US EditionPublished • loading... • Updated
Who Reaffirms the Use of Dolutegravir as a Preferred Option in Early and Post-Hiv Treatment
Summary by diarioestrategia.cl
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
The World Health Organization (WHO) has published updated recommendations on the clinical management of human immunodeficiency virus (HIV) confirming dolutegravir-based regimens (DLT) as the preferred option for initial and subsequent treatment of infection.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
